Falls: A Marker of Preclinical AD
| Condition | Fall, Alzheimer Disease |
|---|---|
| Phase | N/A |
| Sponsor | Washington University School of Medicine |
| Status | Completed |
| Enrollment | 355 participants |
| Start date | Mar 7, 2019 |
| Completion date | Apr 30, 2025 |
| Results posted | Jul 22, 2026 |
Summary
This longitudinal cohort study investigates cognitively normal participants with and without preclinical Alzheimer disease (AD) in order to examine: (1) the relationship between falls and functional mobility in preclinical stages of AD; and (2) a hypothesized model of central and peripheral mechanism(s) underlying falls and functional mobility in preclinical stages of AD.
Fall Severity
| Cohort | 155 Participants |
|---|---|
| Cohort | 100 Participants |
| Cohort | 79 Participants |
| Cohort | 15 Participants |
| Cohort | 107 Participants |
| Cohort | 59 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Brain Energy for Amyloid Transformation in Alzheimer's Disease Study — Wake Forest University Health Sciences
- Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss — Eli Lilly and Company
- Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia — Icahn School of Medicine at Mount Sinai
- Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges — Brigham and Women's Hospital
- Technology and Family Thriving Study — University of California, Santa Barbara
- Community-based Brain Health Program to Address Dementia Risk — Posit Science Corporation